10 September 2025NewsAmericasMercedes Meyer and Brandon Phemester

Killing the golden goose of US drug innovation: Follow the money (Part I)

In the first of a two-part series, Mercedes Meyer of Banner Witcoff and Brandon Phemester of Novavax explore how legislative, judicial, and executive policies have dramatically altered the risks for drug innovation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

The flaw that landed Sanofi a win in the rare disease space

4 September 2025 The company’s EPO victory over a rare disease biomarker patent highlights how precise claims and attention to objections can make or break biotech cases, reports Marisa Woutersen.

Biotechnology

An update on patenting in Ukraine, Russia and Eurasia

2 September 2025 Erik Viik of Papula-Nevinpat looks at the dynamics that international applicants need to be aware of to secure and manage their patent rights across the region.

More features

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Former PTAB judge joins Sterne Kessler

GSK escalates mRNA COVID-19 vaccine dispute

Smart ringleader: Could Ōura’s market dominance be under threat?

The flaw that landed Sanofi a win in the rare disease space

Killing the golden goose of US drug innovation: Follow the money (Part I)

More on this story

Editor's picks

Editor's picks

More features